Lixisenatide: a guide to its use as add-on therapy in type 2 diabetes mellitus

    loading  Checking for direct PDF access through Ovid

Abstract

Lixisenatide (Lyxumia®), a glucagon-like peptide-1 receptor agonist that acts in a glucose-dependent manner to improve glycaemic control, is indicated as add-on treatment for type 2 diabetes mellitus in combination with oral antidiabetic drugs and/or basal insulin when these agents do not provide adequate glycaemic control. In clinical trials in this patient population, add-on therapy with once-daily subcutaneous lixisenatide improved glycaemic control, had beneficial effects on bodyweight and was generally well tolerated.

Related Topics

    loading  Loading Related Articles